You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RDEB

Showing 1 - 25 of 39
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB Trial in Redwood City, Worcester (EB-101 Surgical

Not yet recruiting
  • Epidermolysis Bullosa
  • +2 more
  • EB-101 Surgical application of RDEB wounds
  • Redwood City, California
  • +1 more
Feb 13, 2023

Recessive Dystrophic Epidermolysis Bullosa Trial (Spincare matrix)

Not yet recruiting
  • Recessive Dystrophic Epidermolysis Bullosa
  • Spincare matrix
  • (no location specified)
Jul 12, 2023

Participants Previously Treated With EB-101 for Treatment of

Enrolling by invitation
  • RDEB
  • EB-101
  • Redwood City, California
  • +1 more
Feb 1, 2023

Artificial Intelligence Patient App for RDEB SCCs

Recruiting
  • Epidermolysis Bullosa Dystrophica
  • online survey
  • Chicago, Illinois
    Department of Dermatology, Northwestern University Feinberg Scho
May 3, 2023

Recessive Dystrophic Epidermolysis Bullosa Trial in Redwood City, New York (PTR-01)

Completed
  • Recessive Dystrophic Epidermolysis Bullosa
  • Redwood City, California
  • +1 more
Nov 17, 2022

Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa Trial in Redwood City, Worcester (EB-101)

Active, not recruiting
  • Epidermolysis Bullosa
  • Recessive Dystrophic Epidermolysis Bullosa
  • EB-101
  • Redwood City, California
  • +1 more
Apr 5, 2022

Epidermolysis Bullosa Dystrophica, Squamous Cell Carcinoma Trial in Salzburg (Rigosertib Oral Capsules / Rigosertib Intravenous)

Recruiting
  • Epidermolysis Bullosa Dystrophica
  • Squamous Cell Carcinoma
  • Rigosertib Oral Capsules / Rigosertib Intravenous
  • Salzburg, Austria
    EB House Austria/Dept. of Dermatology University Hospital
Nov 3, 2022

Epidermolysis Bullosa Dystrophica, Recessive Trial in Stanford, Aurora (FCX-007)

Active, not recruiting
Has Results
  • Epidermolysis Bullosa Dystrophica, Recessive
  • FCX-007
  • Stanford, California
  • +1 more
Sep 30, 2021

Epidermolysis Bullosa Dystrophica, Recessive Trial in Paris (COL7A1-SIN retroviral vector engineered autologous

Active, not recruiting
  • Epidermolysis Bullosa Dystrophica, Recessive
  • COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin
  • Paris, France
    Institut Imagine Necker Hospital
Oct 18, 2021

Epidermolysis Bullosa Trial in Aurora, Chicago, New York (Palifermin, Fludarabine, Busulfan)

Terminated
  • Epidermolysis Bullosa
  • Aurora, Colorado
  • +2 more
Aug 13, 2021

Recessive Dystrophic Epidermolysis Bullosa Trial in Salzburg (Genetically corrected cultured epidermal autograft (ATMP))

Terminated
  • Recessive Dystrophic Epidermolysis Bullosa
  • Genetically corrected cultured epidermal autograft (ATMP)
  • Salzburg, Austria
    EB House Austria, Department of Dermatology, Paracelsus Medical
Feb 15, 2022

Pain, Neuropathic, Itch, Epidermolysis Bullosa Trial in Toronto (Pregabalin)

Recruiting
  • Pain, Neuropathic
  • +2 more
  • Toronto, Ontario, Canada
    The Hospital for Sick Children
Jun 9, 2021

Recessive Dystrophic Epidermolysis Bullosa Trial in Redwood City, Aurora, Philadelphia (PTR-01, Normal saline)

Completed
  • Recessive Dystrophic Epidermolysis Bullosa
  • Redwood City, California
  • +2 more
Mar 8, 2021

Recessive Dystrophic Epidermolysis Bullosa Trial in Redwood City, Aurora (PTR-01)

Completed
  • Recessive Dystrophic Epidermolysis Bullosa
  • Redwood City, California
  • +1 more
Sep 14, 2021

Recessive Dystrophic Epidermolysis Bullosa Trial in Los Angeles (Gentamicin)

Unknown status
  • Recessive Dystrophic Epidermolysis Bullosa
  • Los Angeles, California
    University of Southern California
Nov 2, 2020

Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Trial in Stanford (LZRSE-Col7A1 Engineered Autologous Epidermal Sheets)

Active, not recruiting
  • Epidermolysis Bullosa Dystrophica
  • Epidermolysis Bullosa
  • LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
  • Stanford, California
    Stanford University School of Medicine
Oct 23, 2020

Recessive Dystrophic Epidermolysis Bullosa Trial in Seoul (Human Umbilical Cord Blood-derived Mesenchymal Stem Cells)

Completed
  • Recessive Dystrophic Epidermolysis Bullosa
  • Human Umbilical Cord Blood-derived Mesenchymal Stem Cells
  • Seoul, Korea, Republic of
    GangnamSeverance Hospital
Aug 17, 2020

Recessive Dystrophic Epidermolysis Bullosa Trial (Gentamicin, Placebo)

Completed
Has Results
  • Recessive Dystrophic Epidermolysis Bullosa
  • (no location specified)
Oct 15, 2019

Recessive Dystrophic Epidermolysis Bullosa Trial in Worldwide (allo-APZ2-EB)

Completed
  • Recessive Dystrophic Epidermolysis Bullosa
  • allo-APZ2-EB
  • Minneapolis, Minnesota
  • +5 more
Oct 6, 2022

Recessive Dystrophic Epidermolysis Bullosa Trial in United States (FCX-007 (dabocemagene autoficel; see below for FCX-007

Active, not recruiting
  • Recessive Dystrophic Epidermolysis Bullosa
  • FCX-007 (dabocemagene autoficel; see below for FCX-007 description)
  • Stanford, California
  • +4 more
Aug 10, 2022

Recessive Dystrophic Epidermolysis Bullosa Trial in Los Angeles (Gentamicin Sulfate)

Completed
Has Results
  • Recessive Dystrophic Epidermolysis Bullosa
  • Gentamicin Sulfate
  • Los Angeles, California
    University of Southern California
Jul 22, 2019

Recessive Dystrophic Epidermolysis Bullosa Trial in Philadelphia (Rigosertib Sodium, Quality-of-Life Assessment)

Recruiting
  • Recessive Dystrophic Epidermolysis Bullosa
  • Rigosertib Sodium
  • Quality-of-Life Assessment
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Aug 31, 2021

Epidermolysis Bullosa Trial in Minneapolis (allo-APZ2-OTS, Placebo)

Not yet recruiting
  • Epidermolysis Bullosa
  • Minneapolis, Minnesota
    Masonic Cancer Center and Medical Center Minneapolis
Apr 20, 2023

Dystrophic Epidermolysis Bullosa Trial in Stanford (Topical beremagene geperpavec)

Completed
Has Results
  • Dystrophic Epidermolysis Bullosa
  • Topical beremagene geperpavec
  • Placebo gel
  • Stanford, California
    Stanford University
Jan 30, 2023

Epidermolysis Bullosa Trial (allo-APZ2-OTS, Placebo)

Not yet recruiting
  • Epidermolysis Bullosa
  • (no location specified)
Jul 18, 2022